

ANNALS OF HEPATOLOGY

Volume **4**

Number **1**

January-March **2005**

Artículo:

Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data

Copyright © 2005:
Mexican Association of Hepatology

**Otras secciones de
este sitio:**

-  [Índice de este número](#)
-  [Más revistas](#)
-  [Búsqueda](#)

***Others sections in
this web site:***

-  [Contents of this number](#)
-  [More journals](#)
-  [Search](#)



www.Medigraphic.com

Original Article

Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data

Nahum Méndez-Sánchez;¹ Antonio R. Villa;² Norberto C. Chávez-Tapia;¹
Guadalupe Ponciano-Rodríguez;¹ Paloma Almeda-Valdés;¹ Daniela González;¹ Misael Uribe¹

Abstract

Background and Aims. The epidemiology of liver cirrhosis differs across sex, ethnic groups, and geographic regions. In 2000, chronic liver disease was the fifth leading cause of death in Mexico. Accurate knowledge of the demographics of liver disease is essential in formulating health-care policies. Our main aim was to project the trends in liver disease prevalence in Mexico from 2005 to 2050 based on mortality data. **Methods.** Data on national mortality reported for the year 2002 in Mexico were analyzed. Specific-cause mortality rates were calculated for a selected age population (≥ 25 years old) and classified by sex and projected year (2005–2050). The following codes of the International Classification of Diseases for liver diseases were included: non-alcoholic chronic liver disease and cirrhosis, alcoholic liver disease, liver cancer, and acute and chronic hepatitis B and C infection. The projected prevalence of a chronic liver disease was estimated using the following equation: $P = (ID \times T) / [(ID \times T) + 1]$, where P = prevalence, ID = incidence density (mortality rate multiplied by 2), T = median survival with the disease (= 20 years). **Results:** Nearly two million cases of chronic liver disease are expected. Alcohol-related liver diseases remain the most important causes of chronic liver disease, accounting for 996,255 cases in 2050. An emergent syndrome is non-alcoholic liver disease, which will be more important than infectious liver diseases (823,366 vs 46,992 expected cases, respectively). Hepatocellular carcinoma will be the third leading cause

of liver disease. **Conclusions:** Chronic liver disease will be an important cause of morbidity and mortality in the future. Preventive strategies are necessary, particularly those related to obesity and alcohol consumption, to avoid catastrophic consequences.

Key words: Chronic liver disease, alcoholism, obesity, cirrhosis, hepatocellular carcinoma.

Introduction

The epidemiology of liver cirrhosis is characterized by marked differences across sex, ethnic groups, and geographic regions. The nature, frequency, and time of acquisition of the major risk factors for cirrhosis (hepatitis B virus, hepatitis C virus, and alcoholic liver disease) may explain these variations.¹

Hepatitis C virus infection is one of the leading causes of end-stage liver disease requiring liver transplantation. Major centers report that nearly 25%–30% of their candidate pools consist of hepatitis C virus-infected patients.² About four million Americans are presently infected with the virus, and 20%–30% of these patients can be expected to progress to cirrhosis.³ Donor availability is the most significant limiting factor for organ transplantation, and leads to the use of less than perfect organs.

In 2000, chronic liver disease was the fifth leading cause of death in Mexico (Table I). More importantly, it was the second leading cause of death in people aged between 35 and 55 years.⁴ In Mexico, no study has yet examined the long-term data for future trends in the prevalence of chronic liver disease. We believe that this is important because accurate knowledge of the demographics of liver disease is essential in formulating health-care policies to prioritize health interventions and research and to allocate resources accordingly. Currently in our country, some liver diseases (e.g., non-alcoholic fatty liver disease and hepatitis C) have a high, albeit non-quantified, incidence in the population, and others (e.g., hepatocellular carcinoma or fulminant hepatic failure) are highly lethal. Although effective treatments and preventive therapies are available for many types of liver disease, the long-term consequences of ongoing liver damage may require liver transplantation, one of the most involved medical undertakings performed today.

¹ Liver Research Unit, Medica Sur Clinic & Foundation, Mexico City.

² Clinical Epidemiology Unit, National Institute of Medical Sciences and Nutrition, Mexico City, Mexico.

Address for correspondence:

Nahum Méndez-Sánchez, M.D., Ph.D.

Departments of Biomedical Research, Gastroenterology & Liver Unit, Medica Sur Clinic & Foundation, Puente de Piedra 150, Col. Toriello Guerra, Mexico City, Mexico. Phone: (+525) 55606-6222, ext. 4215 Fax: (+525) 55666-4031 and 55606-1651; E-mail: nmendez@medicasur.org.mx

The authors want to dedicated this article to Dr. Ricardo Sosa-Sánchez for his 60 Birthday.

Manuscript received 12 December 2004
and in revised form 31 January 2005.

An epidemiological transition in chronic liver diseases is apparent in Mexico. Therefore, the main aim of this study was to project the trends in the prevalence of liver diseases in Mexico from 2005 to 2050 based on mortality data.

Methods

Experimental procedures

Data on national mortality (death certificates) reported for the year 2002 by the Health Ministry of Mexico were analyzed (www.salud.gob.mx). Specific-cause mortality rates were calculated for a selected age population (≥ 25 years old) and classified by sex for the projected Mexican population (2000–2050) (Consejo Nacional de Población: www.conapo.gob.mx).

Causes of death related to chronic liver diseases were selected in accordance with the International Classification of Diseases, 10th Revision. The following codes for liver diseases were included: non-alcoholic chronic liver disease and cirrhosis (K74.0–K74.6), alcoholic liver disease (K70.0–K70.9), liver cancer (C22.0, C22.7, C22.9), acute and chronic hepatitis B (B16.2, B16.9, B18.0, B18.1), and acute and chronic hepatitis C (B17.1, B18.2). To estimate the preva-

lence of chronic liver disease, the following hypothetical assumptions were made: (a) that the incidence density (ID) of liver disease is at least twice the mortality rate for the selected causes of death, and (b) that the median survival (T) of a person ≥ 25 years of age with chronic liver disease is 20 years. These terms were substituted in the following equation: $P = (ID \times T) / [(ID \times T) + 1]$,⁵ where P = prevalence, ID = incidence density (mortality rate multiplied by 2), T = median survival with the disease (= 20 years). Thus, for each chronic liver disease considered, the prevalence (in terms of absolute number of cases) is reported by sex and projected year (from 2005 to 2050).

Results

Analysis of trends showed an important increase in the prevalence of alcoholic liver disease as the most important cause of hepatic disease in men (*Table II*). Nearly one million cases of liver disease related to this cause are expected in the general population towards 2050. However, in contrast to the male population, non-alcoholic fatty liver disease will be the most prevalent liver disease in women (*Table III*), followed by alcoholic liver disease. Importantly, infectious liver diseases constitute a minority in our predicted trends, representing less than 2% of all liver diseases in men and ~6% of all expected cases in women. The first and second most common etiologies of hepatic disease across both sexes (alcoholic and non-alcoholic liver disease) represent 1,819,621 predicted cases in 2050. Hepatocellular carcinoma will continue as the third leading cause of liver disease, contributing 77,098 cases in the final part of the period evaluated (*Figure 1*).

Discussion

We calculated that both alcoholic and non-alcoholic liver diseases will continue to be the most important liver diseases

Table I. The ten leading causes of deaths in Mexico (2000) [ref. 4].

Rank	Cause	No. of Deaths	%
1	Heart disease	68,716	15.70
2	Malignant neoplasm	54,996	12.57
3	Diabetes mellitus	46,614	10.65
4	Accidents	35,324	8.07
5	Liver diseases	27,426	6.27
6	Cerebrovascular disease	25,432	5.81
7	Perinatal disease	19,394	4.43
8	Pneumonia and influenza	12,301	2.81
9	COPD	10,954	2.50
10	Homicide	10,737	2.45

COPD=Chronic obstructive pulmonary disease.

Table II. Trends in the prevalence of chronic liver diseases in Mexico (men).

	2005	2010	2015	2020	2025	2030	2035	2040	2045	2050
<i>Hepatocellular carcinoma</i>	21162	23908	26626	29287	31512	33159	34425	35399	36067	36377
<i>Alcoholic cirrhosis</i>	504264	569718	634470	697882	750908	790161	820334	843543	859449	866848
<i>Nonalcoholic cirrhosis</i>	309596	349782	389537	428469	461025	485124	503649	517898	527664	532207
<i>Hepatitis B virus infection</i>	2601	2939	3273	3600	3873	4076	4231	4351	4433	4471
<i>Hepatitis C virus infection</i>	6718	7590	8453	9298	10004	10527	10929	11238	11450	11549

Table III. Trends in the prevalence of chronic liver diseases in Mexico (women).

	2005	2010	2015	2020	2025	2030	2035	2040	2045	2050
<i>Hepatocellular carcinoma</i>	23363	26406	29414	32361	34860	36760	38260	39443	40285	40721
<i>Alcoholic cirrhosis</i>	74252	83921	93482	102848	110791	116628	121595	125357	128032	129407
<i>Nonalcoholic cirrhosis</i>	167050	188803	210385	231385	249256	262838	273561	282025	288044	291159
<i>Hepatitis B virus infection</i>	2905	3283	3657	4024	4335	4571	4757	4904	5009	5063
<i>Hepatitis C virus infection</i>	14865	16801	18715	20590	22180	23389	24343	25096	25632	25909




Figure 1. Trends in the prevalence of chronic liver diseases in Mexico. ALD, alcoholic liver disease; NALD, non-alcoholic liver disease; HCC, hepatocellular carcinoma; HCV, hepatitis C virus infection; HBV, hepatitis B virus infection.

es, accounting for nearly 90% of cases in Mexico in 2050. In a previous issue of *Annals of Hepatology*, a collaborative study from the Mexican Association of Hepatology showed the etiology of cirrhosis in Mexico.⁵ As in the 1970s,⁶⁻⁹ alcohol-related cirrhosis remains one of the most important causes of liver disease. Similar data have been reported for other populations. In 1986, 50% of deaths due to cirrhosis in the United States were attributed to alcohol, but in 1997, 40% of deaths from cirrhosis were due to alcohol consumption, with a high economic impact of \$600 million to \$1.8 billion annually.¹⁰ It is important to emphasize that, among men, the mortality rate was highest for Hispanics.¹¹ In a previous study of the Mexican population,¹² geographic situation and pattern of consumption were factors related to the mortality associated with alcoholic liver disease. In the Mexican population, subjects with fewer years of education and lower incomes have the highest rates of alcohol consumption.¹³ Total alcohol consumption in the Mexican population is nine liters per person per year, with a higher prevalence of male drinkers.¹¹ Currently, alcohol is the most common cause of liver cirrhosis. We must emphasize the importance of these observations in any further analysis of other variables associated with increased liver damage and worsening prognoses, particularly factors such as sex, body weight, body mass index, the type and pattern of alcoholic beverage consumed, habitual use of hard liquors, consumption of alcohol without food, and the duration of drinking.¹⁴

The importance of nutritional issues in terms of liver disease was first suggested more than 50 years ago.¹⁵ Currently, it is clear that nutritional imbalance can significantly affect the development of liver diseases.¹⁶ Recently, we analyzed data from the National Survey of Chronic Diseases (ENEC 1993) and the Mexican National Health Survey (ENSA 2000) and observed that the increase in mortality related to liver diseases (particularly cirrhosis) is associated with an increase in the prevalence of overweight patients and obesity.¹⁷ In the present study, we observed an emerging new etiology of cirrhosis,

non-alcoholic fatty liver disease (NAFLD). According to the information we have presented here, NAFLD will be the second most important cause of liver disease in the future, with a higher impact than that of infectious diseases. Furthermore, the Mexican population has a high incidence of overweight members and obesity,¹⁸ and Mexicans are prone to developing the insulin resistance associated with obesity (the phenotype known as “metabolic syndrome”).¹⁹ It has been suggested that insulin resistance is involved in the pathogenesis of NALFD. In Mexico, type 2 diabetes mellitus is the first and second cause of death in women and men, respectively, and the prevalence of NALFD in patients with type 2 diabetes mellitus may be as high as 100%.²¹ Interestingly, a recent study conducted in the United States showed that the Hispanic population has a higher incidence of NAFLD than other populations (45% in Hispanics; 33% in whites; 24% in blacks).²² The pathogenesis of obesity does not just involve racial factors; social, economic, and cultural variables are important issues,²³ particularly among Mexican children,^{24,25} in whom insulin resistance is a risk factor for developing type 2 diabetes mellitus²⁶ and consequent liver disease.

Another problem associated with the predicted high prevalence of chronic liver disease involves the diagnosis of NAFLD. At this time, liver biopsy is the gold standard for this diagnosis. However, a large proportion of subjects with NAFLD are asymptomatic. Therefore, it will be important to develop or improve the tools required for an adequate diagnostic approach.²⁷ We believe that non-invasive diagnostic procedures for NAFLD will be important in preventing chronic liver disease.

Although the rates of infectious liver diseases will become high, patients with hepatitis C virus or hepatitis B virus infections will be numerically less important than those with NAFLD and alcohol-related liver disease. However, obesity and alcohol consumption affect the natural histories of chronic hepatitis infections for viruses B and C and their responses to medical treatment.²⁸⁻³¹ More studies are

required to establish the real incidence of hepatitis C virus and hepatitis B virus infections, because data about their prevalence in the Mexican population are contradictory.

Considering that nearly two million cases of chronic liver disease are expected in the next 50 years, liver transplantation policies must respond to this demand. However, the high costs associated with this therapeutic modality (US\$100,000 per patient per year) necessitate the development of efficient preventive measures to circumvent this catastrophic scenario.¹⁰

Hepatocellular carcinoma will be an important topic in the future, because it is currently fifth in the classification of all malignancies and because Latin American countries are among the areas of highest incidence.³² As a consequence of previously described liver diseases, the identification of risk factors and the adequate treatment of infectious liver diseases are urgently needed. However, obesity is a silent disease and has recently been related to a high risk of developing carcinoma.^{30,33,34} Therefore, modification of lifestyle behavior is an important pathway in preventing one of the most important causes of malignancy.

In conclusion, chronic liver disease will be a significant cause of morbidity and mortality in the near future. It will be necessary to implement preventive measures, particularly those related to obesity and alcohol consumption, to avoid catastrophic consequences.

References

- Mendez-Sanchez N, Uribe M. *Conceptos actuales en Hepatología*. 1st ed. 2003, Mexico: Masson-Doyma.
- Keefe EB. Liver transplantation: current status and novel approaches to liver replacement. *Gastroenterology* 2001; 120: 749-762.
- Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. *Hepatology* 2000; 31: 1014-1018.
- Secretaría de Salud M. Base de datos de información sobre mortalidad in <http://www.salud.gob.mx/apps/htdocs/estadisticas/publicaciones/Mortalidad2000.zip>. Access: 3th january 2005.
- Kleinbaum D, Kupper LL, Morgenstern H. *Epidemiologic Research. Principles and Quantitative Methods*. Van Nostrand Reinhold Company, New York, 1982: 120-121.
- Mendez-Sanchez N, Aguilar-Ramirez JR, Reyes A, Dehesa M, Juarez A, Castneda B, Sanchez-Avila F, Poo JL, Guevara Gonzalez L, Lizardi J, Valdovinos MA, Uribe M, Contreras AM, Tirado P, Aguirre J, Rivera-Benitez C, Santiago-Santiago R, Bosques-Padilla F, Munoz L, Guerrero A, Ramos M, Rodriguez-Hernandez H, Jacobo-Karam J. Etiology of liver cirrhosis in Mexico. *Ann Hepatol* 2004; 3: 30-33.
- Trevino-Zapata N. [Liver cirrhosis. Therapeutic, clinico-functional, anatomo-histopathological concept. Personal previous and current conditions]. *Gac Med Mex* 1969; 99: 162-173.
- Bustamante ME. [Alcoholism and its sociomedical consequences. Socioeconomic aspect]. *Gac Med Mex* 1974; 107: 227-253.
- Aceves Sainos D, Alcocer Murguía F, Hernandez Mateos R, Ibarra S, Marin P, Quijano Z, Valladares Sosa O, Garcia Romero H. [Epidemiology of hepatic cirrhosis]. *Rev Gastroenterol Mex* 1975; 40: 26-32.
- Dajer F, Guevara L, Arosamena L, Suarez GI, Kershenobich D. [Epidemiological aspects of alcoholic liver cirrhosis in Mexico]. *Rev Invest Clin* 1978; 30: 13-28.
- Kim WR, Brown RS, Jr., Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. *Hepatology* 2002; 36: 227-242.
- Mandayam S, Jamal MM, Morgan TR. Epidemiology of alcoholic liver disease. *Semin Liver Dis* 2004; 24: 217-232.
- Narro-Robles J, Gutierrez-Avila JH. [Ecological correlation between consumption of alcoholic beverages and liver cirrhosis mortality in Mexico]. *Salud Publica Mex* 1997; 39: 217-220.
- Lopez-Jimenez JL. [Alcohol consumption patterns in patients admitted to emergency services]. *Salud Publica Mex* 1998; 40: 487-493.
- Gordon H. Detection of alcoholic liver disease. *World J Gastroenterol* 2001; 7: 297-302.
- Fabregoule M, Eisenbeth R. [The role of nutritional factors in the etiology of hepatitis and cirrhosis]. *Alger Medecale* 1950; 54: 119-123.
- Ratzu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T. Liver fibrosis in overweight patients. *Gastroenterology* 2000; 118: 1117-1123.
- Mendez-Sanchez N, Sanchez-Castillo CP, Villa AR, Madrigal H, Merino B, Garcia E, Lopez P, Pichardo-Ontiveros E, Uribe M. The relationship of overweight and obesity to high mortality rates from liver cirrhosis in Mexico. *Ann Hepatol* 2004; 3: 66-71.
- Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. *JAMA* 2004; 291: 2847-2850.
- Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. *JAMA* 2002; 287: 356-359.
- Mendez-Sanchez N, Sanchez-Lara K, Villa AR, Bahena-Aponte J, Chavez-Tapia NC, Ramos MH, Uribe M. Adiponectin concentration as protective factor in hepatic steatosis. *World J Gastroenterol* 2005; in press.
- Tolman KG, Fonseca V, Tan MH, Dalpiaz A. Narrative review: hepatobiliary disease in type 2 diabetes mellitus. *Ann Intern Med* 2004; 141: 946-956.
- Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. *Hepatology* 2004; 40: 1387-1395.
- Power C, Manor O, Matthews S. Child to adult socioeconomic conditions and obesity in a national cohort. *Int J Obes Relat Metab Disord* 2003; 27: 1081-1086.
- Melgar-Quinonez HR, Kaiser LL. Relationship of child-feeding practices to overweight in low-income Mexican-American preschool-aged children. *J Am Diet Assoc* 2004; 104: 1110-1119.
- Sherry B, Mei Z, Scanlon KS, Mokdad AH, Grummer-Strawn LM. Trends in state-specific prevalence of overweight and underweight in 2- through 4-year-old children from low-income families from 1989 through 2000. *Arch Pediatr Adolesc Med* 2004; 158: 1116-1124.
- Batey LS, Goff DC, Jr., Tortolero SR, Nichaman MZ, Chan W, Chan FA, Grunbaum J, Hanis CL, Labarthe DR. Summary measures of the insulin resistance syndrome are adverse among Mexican-American versus non-Hispanic white children: the Corpus Christi Child Heart Study. *Circulation* 1997; 96: 4319-4325.
- Brunt EM, Neuschwander-Tetri BA, Oliver D, Wehmeier KR, Bacon BR. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. *Hum Pathol* 2004; 35: 1070-1082.
- Younossi ZM, McCullough AJ, Ong JP, Barnes DS, Post A, Tavill A, Bringman D, Martin LM, Assmann J, Gramlich T, Mullen KD, O'Shea R, Carey WD, Ferguson R. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. *J Clin Gastroenterol* 2004; 38: 705-709.
- Safdar K, Schiff ER. Alcohol and hepatitis C. *Semin Liver Dis* 2004; 24: 305-315.
- Jee SH, Ohrr H, Sull JW, Samet JM. Cigarette smoking, alcohol drinking, hepatitis B, and risk for hepatocellular carcinoma in Korea. *J Natl Cancer Inst* 2004; 96: 1851-1856.
- Weber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon SM. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. *JAMA* 1985; 254: 3187-3189.
- Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. *Liver Transpl* 2003; 9: 331-338.
- Gonzalez L, Blanc JF, Cunha AS, Rullier A, Saric J, Bail BL, Balabaud C, Bioulac-Sage P. Obesity as a risk factor for hepatocellular carcinoma in a noncirrhotic patient. *Semin Liver Dis* 2004; 24: 415-419.
- Regimbeau JM, Colombat M, Mognol P, Durand F, Abdalla E, Degott C, Degos F, Farges O, Belghiti J. Obesity and diabetes as a risk factor for hepatocellular carcinoma. *Liver Transpl* 2004; 10: S69-S73.